Finding key to cancer drug Gleevec's limitations

ANN ARBOR, Mich. -- University of Michigan researchers have developed an animal model that provides strong evidence why imatinib, marketed as Gleevec, helps patients with chronic myeloid leukemia survive longer, but does not keep the disease from returning if treatment ends.

Read the whole article on Science Blog

More from Science Blog